MolPort expansion enables more efficient compound and reagent sourcing in US
E-commerce platform serves scientists by providing a wide selection of compounds from trusted worldwide suppliers for easy search, convenient ordering and hassle-free delivery.
MolPort, a dedicated full-service e-commerce platform with extensive expertise in compound sourcing, has expanded into the US with the opening of MolPort Inc. This new business unit will further streamline the compound ordering process for its many US customers, who will benefit from faster, more efficient ordering and payment procedures, as well as improved customs navigations.
MolPort combines specialized expertise and innovative software tools for compound sourcing with an extensive database of over 7.6 million stock compounds from more than 60 industry-leading suppliers. In doing so, MolPort enables scientists to focus on their research and not on the often lengthy and complex procurement process.
For over a decade, MolPort’s core expertise in compound sourcing has been helping scientists accelerate drug discovery and compound screening programmes. The company provides one of the most trusted and reliable selections of screening compounds and building blocks to benefit computational and medicinal chemists, among others. By combining natural compounds and other small molecules and building blocks from multiple suppliers, scientists are able to place a single order that includes entities from across different catalogues to generate the best library for their requirements.
MolPort consolidates its commercially available compound database by integrating catalogues from multiple suppliers to produce a single searchable e-commerce platform. It is simple and intuitive to use and is updated and synchronized with supplier inventories on a daily basis. The database can be accessed through an advanced and powerful structure search or list search. Ordering can take place via the online e-shop, or integrated with a company’s procurement system. MolPort’s expert customer service team is easy to reach and fully equipped to use and advise on existing database tools to help build customer libraries, as well as create custom solutions for their clients. The expertise and knowledge of the MolPort team means that they are well-placed to consult with customers to precisely understand their requirements, build personalized libraries, and provide detailed product-specific information and integration solutions.
Dr Nicholas Malmquist, Institut Pasteur, commented: “I found MolPort when I was looking to re-source screening hit compounds. The MolPort website is very intuitive and makes it easy to search for exactly what you need or even similar related compounds. The ordering process is very easy and they take care of sourcing and shipping from multiple suppliers. MolPort is my first stop now for sourcing small molecules.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance